Outcomes of Pharmaceutical Care Development in Pediatric Patients with Thalassemia Using Deferiprone in Phrae Hospital

Main Article Content

Sumalee Sanguansak
Wannakamol Sonsingh
Kanokporn Niwatananun


Introduction: Thalassemia patients with iron overload and had to take iron chelator-deferiprone likely to have drug therapy problems (DTPs) that affected the treatment outcome assessed by an unmet goal of reduction in serum ferritin levels and incidence of adverse events. Therefore, pharmaceutical care services were developed to solve the problems. . This study aimed to evaluate the outcome of pharmaceutical care development in pediatric thalassemia patients taking derferiprone by assessing reduction of serum ferritin levels and occurrence of DTPs. Materials and Method: A quasi-experimental research, with one group pretest-posttest design was carried out in 39 pediatric thalassemia patients taking deferiprone and visiting at the Department of Pediatrics, Phrae Hospital during October 1, 2010 to May 31, 2015. The study period was divided into three periods, including pre-pharmaceutical care, the first phase of pharmaceutical care and the second phase of pharmaceutical care. Results: Mean serum ferritin levels in month 0, 6 and 12 during the first phase of pharmaceutical care decreased significantly (2316.4, 1695.1 and 1269.7 nanogram/milliliter respectively; p <0.001), whereas serum ferritin levels in months 0, 6 and 12 of pre- pharmaceutical care period and the second phase of pharmaceutical care  were  not different (p = 0.347). Based on 22 patients who have serum ferritin levels in all three phases. In addition, number of  non-compliance significantly declined in the second phase of pharmaceutical care compared to those in the first phase of pharmaceutical care (p=0.019) (n=39). Conclusion: Outcome of pharmaceutical care development can reduce serum ferritin levels, and resolves non-compliance, in pediatric thalassemia patients.

Article Details

Pharmaceutical Practice


Angelucci E, Brittenham GM, McLaren CE, et al. Hepatic iron concentration and total body iron stores in thalassemia major. N Engl J Med 2000; 343(5): 327-331.

Borgna-Pignatti C, Cappellini MD, De Stefano P, et al. Survival and complications in thalassemia. Ann N Y Acad Sci 2005; 1054: 40-47.

Ceci A, Baiardi P, Felisi M, et al. The safety and effectiveness of deferiprone in a large-scale, 3-year study in Italian patients. Br J Haematol 2002; 118(1): 330-336.

Chanpongsang K, Lauwahutanont S. The Results of Iron Chelating Drug in Beta-thalassemic Patients Phra Nakhon Si Ayutthaya Hospital. J Pre Med Assoc Thai 2013; 3(1): 25 - 30.

Cohen AR, Galanello R, Piga A, Dipalma A, Vullo C and Tricta F. Safety profile of the oral iron chelator deferiprone: a multicentre study. Br J Haematol 2000; 108(2): 305-312.

Cohen AR, Galanello R, Piga A, De Sanctis V and Tricta F. Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone. Blood 2003; 102(5): 1583-1587.

Fucharoen S, Tanphaichitr V, Torcharus K, Viprakasit V, editors. Clinical practice guidelines for diagnosis and management of thalassemia syndromes. P.A. Living Limited; 2014. 25-31.

Gardenghi S, Marongiu MF, Ramos P, et al. Ineffective erythropoiesis in beta-thalassemia is characterized by increased iron absorption mediated by down-regulation of hepcidin and up-regulation of ferroportin. Blood 2007; 109(11): 5027-5035.

Hershko C. Pathogenesis and management of iron toxicity in thalassemia. Ann N Y Acad Sci 2010; 1202: 1-9.

Pakbaz Z, Fischer R, Fung E, Nielsen P, Harmatz P and Vichinsky E. Serum ferritin underestimates liver iron concentration in transfusion independent thalassemia patients as compared to regularly transfused thalassemia and sickle cell patients. Pediatr Blood Cancer 2007; 49(3): 329-332.

Piga A, Roggero S, Longo F, et al. Evaluation and treatment of secondary iron overload. In: Beaumont C, Beris P, Benzard Y, et al., editors. Disorders of Erythropoiesis, Erythrocytes and Iron Metabolism. Marseille, France: European Society of Haematology Handbook: Club de Globule et du Fer; 2009. 585-604.

Tanner MA, Galanello R, Dessi C, et al. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance. Circulation 2007; 115(14): 1876-1884.

Telfer P, Coen PG, Christou S, et al. Survival of medically treated thalassemia patients in Cyprus. Trends and risk factors over the period 1980-2004. Haematologica 2006; 91(9): 1187-1192.

Tocharus K. Thalassemia Syndrome. In: Prayoonwiwat W, Jootar S, Srichaikul T,editors. Textbook Hematology: Diagnosis and treatment of blood diseases that are common in Thailand. 3rd ed. Nam Akson Printing House; 2007: 255-270.

Viprakasit V. Clinical Practice Guideline for Deferiprone in Patients with Iron Overload. Sponsored by Goverment Pharmaceutical Organization; 2009.